To compare the HER2-targeting standard of care, Herceptin, to the CAM1615HER2 TriKE, both were included in assays against breast cancer (SK-BR-3) and ovarian cancer (SKOV-3) cells, and both drugs induced comparable NK cell activation (Supplementary Figure S2A,B and Figure 2F,G respectively). This evidence concerns the gene ERBB2 and breast cancer.